Medical device developer TriVascular Technologies Inc. hopes to expand sales and marketing, fund additional research and pay off a note to Boston Scientific Corp. with a planned $100 million initial public offering. The Santa Rosa maker of devices that help doctors repair abdominal aortic aneurysms, led by Chairman, President and CEO Christopher Chavez, would trade on the Nasdaq exchange as “TRIV.” J.P. Morgan Securities LLC and Credit Suisse Securities are joint book-running managers for the offering.
Help employers find you! Check out all the jobs and post your resume.
